21 results about "RUNX2" patented technology

Provided herein are methods and compositions for differentiating induced pluripotent stem cells into granulosa-like cells by overexpressing transcription factors such as NR5A1 and a RUNX family protein (e.g., RUNXI and / or RUNX2).

The invention discloses a sterone compound derived from achyranthes bidentata as well as a preparation method and application of the sterone compound. Belongs to the technical field of biological medicine. The invention aims to solve various side effects and defects of the existing medicine for treating glucocorticoid-induced osteoporosis in long-term use. The molecular formula of the compound (SSA) is C33H48O9, the compound (SSA) has a beta-ecdysterone skeleton, and acetal type 5-hydroxymethylfurfural groups are introduced at the positions of side chains C20 and C22. SSA has a remarkable protection effect in a DEX-induced osteoblast injury model, can improve cell viability decline and G1 phase retardation caused by glucocorticoid, and recovers osteogenic differentiation and mineralization ability. The SSA effectively reverses the inhibition effect of DEX on osteoblasts by activating a Wnt / beta-catenin signal channel and up-regulating the expression of RUNX2. SSA has a remarkable anti-osteoporosis function potential.

The invention relates to application of harmine in preparation of a medicine for preventing and treating vascular calcification. The harmine can be used for preventing and / or treating vascular calcification. Experiments show that harmine reduces osteogenic differentiation of vascular smooth muscle cells by down-regulating expression of RUNX2 and BMP2 and up-regulating expression of alpha-SMA at the same time, calcium salt deposition of blood vessels can be reduced, and it is indicated that harmine has a remarkable inhibition effect on vascular calcification. The new application of harmine in the anti-vascular calcification aspect is confirmed, so that the research of harmine in the technical field of medicines can be expanded, a new way is provided for research and development of drugs for treating vascular calcification, and a new theoretical direction is provided for clinical application.

This invention relates to the field of biomedical technology, specifically disclosing an anti-inflammatory and bone-promoting rhodioloside composite hydrogel and its preparation method. The thermosensitive carrier is a triple-response system, which enhances the drug release rate only in a specific microenvironment at 37°C, with a pH of 5.5-6.5 at the site of inflammation, and in which MMPs are overexpressed. MMPs are highly expressed at the implant periodontitis site, and MMP-sensitive peptides can be specifically degraded by this enzyme. This process can trigger the precise release of rhodioloside and quercetin active ingredients in the gel, avoiding systemic drug diffusion that could lead to drug waste or side effects at other sites. Rhodioloside and quercetin synergistically downregulate the expression levels of inflammatory factors such as IL-6 and TNF-α, while nisin and chitosan-ε-polylysine grafts inhibit the growth of Porphyromonas gingivalis. Runx2 / CON expression is increased, achieving a closed-loop treatment of anti-inflammatory, antibacterial, and bone-promoting effects.

This invention belongs to the field of biomedical technology and relates to the application of OSM inhibitors in the preparation of drugs for the prevention or treatment of calcific aortic valve disease. This invention reveals for the first time that OSM drives osteogenic differentiation and calcified nodule formation of valvular interstitial cells through the OSM-OSMR-JAK2 / JAK3-STAT3-RUNX2 signaling axis, which is the core pathogenic mechanism leading to calcific aortic valve disease. This invention utilizes anti-OSM neutralizing antibodies or sulforaphane to effectively block this signaling axis, significantly inhibiting macrophage infiltration, valvular calcification, and improving hemodynamic abnormalities. This invention provides a precise target and a novel strategy for the modification therapy of calcific aortic valve disease, solving the technical problem of the ineffectiveness of traditional broad-spectrum anti-inflammatory therapy in valvular calcification.

The present invention relates to novel long non-coding RNAs (lncRNA) involved in the regulation of hypertrophy of chondrocytes, wherein RUNX2 was regulated at the post-translational level during hypertrophic differentiation of the chondrocyte cell line TC28a2 and two novel RUNX2-binding lncRNAs among numerous lncRNAs were identified, leading to the present invention. It is expected that bone-related diseases can be diagnosed by measuring the expression of the identified specific lncRNAs, and furthermore, the vascularization or calcification of articular cartilage can be effectively suppressed by inhibiting the hypertrophy of chondrocytes through inhibiting the expression of the identified specific lncRNAs, which is expected to be highly effective in the prevention or treatment of bone-related diseases.

The invention provides an embryonic stem cell differentiation technology and application of the embryonic stem cell differentiation technology in screening of unknown risk alternative toxicity of a novel biological breeding product, and Cry1Ab protein is used as a test substance to evaluate the developmental toxicity of the Cry1Ab protein. The EBs are generated through hanging drop culture, and bone differentiation induction substances (beta-glycerophosphate, ascorbic acid and vitamin D3) are added to promote differentiation of the EBs. After bone cell induced differentiation is finished, the differentiation condition of bone cells is observed through alizarin red S dyeing and absorbance value detection, the cell growth condition is observed through cell total protein concentration and alkaline phosphatase activity detection, and then the influence of a test substance on the bone differentiation process is analyzed through the gene expression condition of osteogenic differentiation related markers (Runx2, SPARC and I-type collagen). The invention solves the problem of evaluating the unknown risk of a novel biological breeding product in vitro, creates an embryonic stem cell bone differentiation test technology, and uses the embryonic stem cell bone differentiation test technology as a screening method for the unknown risk alternative toxicity of the novel biological breeding product to be combined with an embryonic stem cell myocardial differentiation experiment for use. And the accuracy of predicating the developmental toxicity of the test substance is improved.

Provided are a prophylactic or therapeutic agent for Crohn's disease, and a method for examining Crohn's disease. The prophylactic or therapeutic agent for Crohn's disease contains at least one selected from the group consisting of a RUNX2 inhibitor and a BHLHE40 inhibitor. The method for examining Crohn's disease includes (1) a step for detecting a protein and / or mRNA of at least one gene selected from the group consisting of RUNX2 and BHLHE40 in digestive tract-derived immune cells collected from a subject.

The present application relates to the field of medicine biotechnology, especially the application of RUNX2 as a marker in the preparation of a breast malignant phyllodes tumor diagnosis or detection reagent. The reagent can assist conventional biopsy according to the expression level of RUNX2 in different grades of breast phyllodes tumor, and can diagnose, differentially diagnose, grade and prognostically analyze the breast phyllodes tumor. The RUNX2 detection primer sequence and detection antibody of the present application are important components of the diagnosis or detection reagent or kit, so that the detection of breast malignant phyllodes tumor is more simple, fast and accurate, has good clinical application value, helps to further improve the diagnosis level of breast malignant phyllodes tumor, and is expected to become the first diagnosis and detection kit for breast malignant phyllodes tumor.

The invention relates to the technical field of biological treatment of bone metabolic diseases, and discloses an application of a bone-strengthening and blood-generating oral liquid in preparation of a medicine for treating osteoporotic fracture.The application includes the steps that when the medicine is prepared, active components in the bone-strengthening and blood-generating oral liquid are combined with a Wnt signal transduction complex in osteoblasts in a targeted mode, and the bone-strengthening and blood-generating oral liquid is obtained; the phosphorylation activity of glycogen synthase kinase-3 is inhibited, so that-catenin enters a nucleus, Runx2 expression is started, and the synthesis rate of the N-terminal propeptide of the type I procollagen is increased; according to the method, a positive anabolism window is established in an original callus formation period of fracture healing by constructing an osteogenesis and osteoclast activity two-way decoupling biological regulation mechanism, so that a positive anabolism effect is achieved, and a positive anabolism effect is achieved. Bone metabolism pathological deviation in an osteoporosis state is corrected, secondary absorption of callus is inhibited while high osteogenic activity is maintained, and biomechanical fracture load of bones after fracture healing is improved.

The application belongs to the technical field of medicine, and particularly relates to application of alpha-ketobutyric acid in preparation of a medicine for preventing and / or treating vascular calcification. Through a high-phosphorus-induced vascular smooth muscle cell calcification model and a vitamin D3-induced mouse aorta calcification model, the application first proves that alpha-ketobutyric acid can significantly inhibit vascular calcium salt deposition, reduce osteogenic-like transdifferentiation of vascular smooth muscle cells, and down-regulate expression of osteogenic-related markers such as RUNX2 and BMP2. In addition, alpha-ketobutyric acid and sodium hydrosulfide in combination show a synergistic effect. The application provides a new medicine selection and strategy for prevention and treatment of vascular calcification and related cardiovascular diseases.

Provided herein are methods and compositions for differentiating induced pluripotent stem cells into granulosa-like cells by overexpressing transcription factors such as NR5A1 and a RUNX family protein (e.g., RUNX1 and / or RUNX2).

The invention discloses a nucleic acid aptamer of RUNX2 protein and application of the nucleic acid aptamer, and belongs to the technical field of biology, the nucleotide sequence of the nucleic acid aptamer is shown as SEQ ID NO.1, the nucleic acid aptamer has the advantages of being small in molecular weight, stable in chemical property, easy to store and mark and the like, the nucleic acid aptamer is obtained through screening based on the SELEX technology, the nucleic acid aptamer can be combined with the RUNX2 protein with high affinity and high specificity, and the nucleic acid aptamer can be used for detecting the RUNX2 protein. The affinity constant is as low as 8.88 nM, and the synthesis cost is low. The nucleic acid aptamer provided by the invention shows good application prospects in the aspects of disease detection, diagnosis, molecular imaging, targeted therapy and the like.

The invention discloses application of GDF6 in preparation of a medicine for detecting periodontitis or preventing and treating periodontitis, and belongs to the technical field of biological medicine. The invention finds that GDF6 is obviously reduced in periodontitis gingival tissues; the GDF6 can improve the expression of ALP, cell mineralization and the expression of osteogenic transformation related genes ALP, RUNX2 and OCN by reducing the expression of inflammatory factors of the inflammatory PDLSCs, so that the GDF6 can be used for osteogenic differentiation of the PDLSCs in an inflammatory state. In addition, the GDF6 can significantly improve the level of periodontitis of mice and alveolar bone resorption when applied in vivo, so that the GDF6 has a good treatment effect on periodontitis.

This invention discloses a specific expression regulatory element for the hornless target gene RXFP2 in goats and its application. The sequence of the regulatory element is SEQ ID No. 1. Through single-cell gene expression and chromatin accessibility analysis of fetal bovine horn bud tissue, this invention discovered a specific, open regulatory element (chr12:29279059-29279559) upstream of RXFP2 in horn bud tissue. This element possesses a binding motif for RUNX2, a core transcription factor promoting osteoprogenitor cell differentiation, and is highly conserved in horned animals. Its location in the goat genome is chr12:57440948-57441449. Dual-luciferase assays verified that this regulatory element mediates the interaction between transcription factors RUNX2 and RXFP2, achieving specific high expression of RXFP2 in horn bud tissue. By knocking out the regulatory element region (chr12:57440800-57441678) in goat embryos using CRISPR-Cas9, goat embryos with gene-edited knockout of the hornless target gene RXFP2 specifically expressing regulatory elements were successfully prepared. This invention further elucidates the origin, evolution, and skin ossification mechanisms of horn organs, providing new targets for hornless livestock breeding.

The invention discloses a lung targeting nucleic acid drug-carrier composition, a preparation method and application, and belongs to the technical field of biological medicine. The composition takes an FEN1-DNP deoxyribonucleoprotein compound as a core treatment component, the compound is formed by assembling FEN1 endonuclease and an hpDNA oligonucleotide probe, the pulmonary fibrosis core pathogenic genes RUNX2 and PAI-1 can be precisely cut in a targeted manner, and the pathological process of a disease is cooperatively intervened in multiple links. A delivery carrier adopts composite lipid nanoparticles composed of ionized lipid, cationic lipid, neutral phospholipid, cholesterol and pegylated lipid, an FEN1-DNP compound is efficiently entrapped through a microfluidic method, and the composition adapts to aerosol inhalation administration, can directly reach a lung focus, improves the drug lung tissue enrichment degree, reduces the toxicity of non-target organs of the whole body, and has a good application prospect. The method has the advantages of multi-target intervention, high targeting and high biological safety, and has remarkable clinical transformation potential in the field of pulmonary fibrosis treatment.

The application provides application of ipomoea nil exocyst in preparation of a medicine for preventing, alleviating or treating osteomyelitis. The application creatively finds that the ipomoea nil exocyst can significantly inhibit the expression of macrophage pyroptosis markers GSDMD-NT and Caspase-1, promote the expression of osteogenesis markers RUNX2 and OPN, and mediate immune regulation to achieve the treatment of osteomyelitis. The ipomoea nil exocyst is loaded in a three-dimensional cross-linked skeleton formed by oxidized dextran, aminopolysaccharide and gelatin, has better mass transfer delivery effect, and significantly improves the treatment effect on osteomyelitis.

The invention belongs to the field of stem cell genetic engineering, and provides application of NLRP12 in anti-inflammatory osteogenesis promotion of periodontal ligament stem cells. According to the NLRP12 overexpression PDLSCs, the anti-inflammatory gene is applied to periodontal regeneration treatment, and the anti-inflammatory capacity and the tissue defect repairing capacity after the PDLSCs are transplanted into a body are effectively improved. An exogenous gene is transferred into PDLSCs through a virus vector, stable transfection and efficient and continuous expression of an anti-inflammatory gene are achieved, and the repair effect of periodontitis tissue defects is promoted. In-vitro experiments show that NLRP12 overexpression in an inflammatory microenvironment alleviates the inflammatory response and osteogenic differentiation inhibition of PDLSCs, which shows that the expression of proinflammatory factors IL-6 and IL-8 is down-regulated, the expression levels of anti-inflammatory factors IL-10 and osteogenic related proteins RUNX2, COL1 and BMP2 are up-regulated, ALP dyeing and alizarin red dyeing are deepened, and mineralized nodule formation is increased. The NLRP12 overexpression PDLSCs is applied to a rat experimental periodontitis model in vivo, inflammatory reaction is remarkably relieved, and periodontal tissue regeneration of periodontitis rats is promoted. Mechanism research shows that the NLRP12 alleviates the inflammatory response of PDLSCs and osteogenic differentiation inhibition by inhibiting an NF-kappa B pathway. The NLRP12 overexpression PDLSCs are suitable for repairing periodontal tissue defects, and have a good clinical application prospect.

The application discloses application of Phascolosoma esculenta exosome in preparation of a preparation for promoting osteogenic differentiation of bone marrow mesenchymal stem cells, and belongs to the technical field of marine biological medical materials. Fresh and live Phascolosoma esculenta is used as raw material, body cavity fluid is collected, and Phascolosoma esculenta exosome is obtained through separation and purification by means of fractional filtration, differential centrifugation and ultracentrifugation. The exosome has uniform particle size, high biocompatibility and no cytotoxicity, can significantly promote proliferation of human bone marrow mesenchymal stem cells in a low concentration range of 5-10 μg / mL, up-regulate expression levels of ALP, RUNX2 and OPN osteogenic marker proteins, improve alkaline phosphatase activity, promote calcium nodule deposition, accelerate osteogenic differentiation of stem cells, and has good biological medicine development prospect and industrial application value.

The invention belongs to the technical field of medicines, and particularly relates to application of alpha-ketobutyric acid in preparation of a medicine for preventing and / or treating vascular calcification. Through a high-phosphorus-induced vascular smooth muscle cell calcification model and a vitamin D3-induced mouse aorta calcification model, it is proved for the first time that alpha-ketobutyric acid can significantly inhibit vascular calcium salt deposition, reduce osteogenic transdifferentiation of vascular smooth muscle cells and down-regulate expression of osteogenic related markers such as RUNX2 and BMP2. In addition, the alpha-ketobutyric acid and the sodium hydrosulfide are combined for use to show a synergistic effect. The invention provides a new drug selection and strategy for prevention and treatment of vascular calcification and related cardiovascular diseases.

The application relates to an inhibitor targeting Cx43 and application. The inhibitor innovatively adopts natural hedyotis diffusa exosome as a core carrier, forms a complex through self-assembly with hyaluronic acid, and is further surface-modified with cationic chitosan to construct a ternary delivery system of "exosome-hyaluronic acid-chitosan". The system can efficiently load and protect therapeutic nucleic acid molecules, and significantly improve the in-vivo stability of the nucleic acid molecules. The hyaluronic acid endows the carrier with active targeting ability to bone tissue cells, and the chitosan improves the cell uptake efficiency. After the loaded miR-206 enters target cells, the expression of gap junction protein Cx43 can be specifically down-regulated, and then the ERK1 / 2-Runx2 signal path is regulated. The preparation shows good application potential in inhibiting Cx43.